

Morning Moves Dec 23, 2021



- At the current juncture, 16980 levels hold as resistance for the benchmark index Nifty50 above which the index may likely witness upside towards 16980 levels on a broad range. On the up side, the index may navigate towards 17180 levels, which has seen a significant built up in open interest.
- Technically, the index is having support around the 16900 zone and any sustenance up it may
  negate the current bullish sentiments in the market and may navigate up in the near future.
- On technical setup, Nifty Banks and Financial Services looks bullish as seen on the intraday chart closing up the support zone.

INTRADAY RECOMMENDATIONS						
Scrip Code	Act	Entry	SL	TGT		
ADANI PORT	S	725	735	710		
ASHOK LEYLAND	L	124	121	130		
BANDHAN BANK	L	250	246	260		
APOLLO HOSPITALS	S	4800	4900	4650		

NIFTY	
S1:- 16900	
S2:- 16780	
R1:- 16980	
R2:- 17180	

BANKNIFTY	
S1:- 34950	
S2:- 34750	
R1:- 35300	
R2:- 35500	



NIFTY
INDIA VIX 16.58
0.85 PCR 23 DEC EXP
1.10 PCR 30 DEC EXP
1.07 PCR 06 JAN EXP
0.83 PCR 13 JAN EXP

### **INTRADAY RECOMMENDATIONS**

Stock Action		Entry	Stop Ioss	Target	
ADANI PORT	S	725	735	710	



**ADANI PORT** has witnessed a resistance around 745 levels and closed well below the same in the last trading session. The stock is expected to maintain it's down. The recent development in the stock suggests that stock is well placed to take an down move.

Stock	Action	Entry	Stop loss	Target
ASHOK LEYLAND	L	124	121	130



**ASHOK LEYLAND** is momentum in the last trading session and has witnessed a reversal on the back of supportive volume formation on daily charts. The momentum in the stock is expected to continue in coming session. The stock is expected to maintain it's up move in coming trading session.

Stock	Action	Entry	Stop Ioss	Target
BANDHAN	L	250	246	260



**BANDHAN BANK** has witnessed a bounce from around 242 support levels and closed well above the same in the last trading session. The stock is expected to maintain it's up move post taking support from the breakout zone. The recent development in the stock suggests that stock is well placed to take an up move.

Stock	Action	Entry	Stop loss	Target
APOLLO HOSPITALS	S	4800	4900	4650



**APOLLO HOSPITALS** witnessed resistance around 4910 levels and has witnessed selling from the same on the back of supportive volumes indicating bearishness in the counter. On technical front, 14 periods RSI is also supporting the bearish view in the counter and even on the Bollinger band the stock has headed towards the lower band.





### Kabhi Khushi, Kabhi Gham Life mein balance zaruri hai



### **New Fund Offer**

Opened on: 9th Dec, 2021 & Closes on: 23rd Dec, 2021

Scheme reopens for continuous sale and repurchase from: 3rd January, 2022

# Mahindra Manulife <sub>ı</sub> Balanced Advantage Yojana<sub>ı</sub>

An open ended dynamic asset allocation fund

## Contact your Mutual Fund Distributor Now



Investors understand that their principal

#### This product is suitable for investors who are seeking

- Capital Appreciation while generating income over medium to long ter
- Investments in a dynamically managed portfolio of equity and equity related instruments and debt and money market instruments.

\*Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The product labelling /risk level assigned for the Scheme during the New Fund Offer is based on internal assessment of the Scheme's characteristics or model portfolio and the same may vary post New Fund Offer when the actual investments are made.



MUTUAL FUND

Cno.01134

The information contained herein are not for distribution and do not constitute an offer to buy or sell or solicitation of an offer to buy or sell any schemes/Units of Mahindra Manulife Mutual Fund / securities in the United States of America ("US") and/or Canada or for the benefit of US Persons (being persons falling within the definition of the term "US Person" under the US Securities Act of 1933 or as defined by the U.S. Commodity Futures Trading Commission, as amended) or residents of Canada as defined under applicable laws of Canada.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.



Age Band/SUC	Graduate			Non - Graduate				
. G. Land	18-35 yrs	36 - 45 yrs	46-60 yrs	61-65 yrs	18 - 35 yrs	36 - 45 yrs	46-60 yrs	61-65 yrs
up to 10,00,000								
10,00,001 - 15,00,000								NIL
15,00,001 - 50,00,000								
50,00,001 - 75,00,000				NIL			NIL	
75,00,001 - 1,00,00,00					NIL	NIL		
1,00,00,001 - 1,50,00,000			NIL					
1,50,00,001 - 2,50,00,000	NIL	NIL.						
	MER+A1+	MER + A1 +	MER+A1+	MER+A1+	MER+A1+	MER+A1+	MER+A1+	MER+A1
	B1+C+D+	B1+C+D+	B1+C+D+	B1+C+D+	B1+C+D+	B1+C+D+	B1+C+D+	B1+C+D
> 2,50,00,000	ECG	CTMT	CTMT	CTMT	ECG	СТМТ	CIMT	СТМТ

#### **QUERIES & FEEDBACK**

VP-Head Research - Dr. Ravi Singh Mob: +919810313561

Email ID: ravi.singh@shareindia.com

We, research team at Share India Securities Ltd. (SISL), authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. SISL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related tothe specific recommendation(s) or view(s) in this report.

We state that Research Analyst or his/her relative or SISL may have any financial interest in the subject company. Also Research Analyst or his relative or SISL or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further, Research Analyst or his relative or SISL or its associate a) does not have any material conflict of interest at the time of publication of the research report; b) has not managed or co-managed public offering of securities for the subject company in the past twelve months; c) has not received any compensation for investment banking or brokerage services or for any other product/s or service/s or for any other reason whatsoever from the subject company in the past twelve months; d)has not received any compensation or other benefits from the subject company or third party in connection with the research report; e) has not served as an officer, director or employee of the subject company; and f) has not been engaged in market making activity for the subject company.

SISL is a SEBI Registered Research Analyst having registration no. INH100005011.

#### Disclaime

This report has been prepared by SISL and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based uponinformation obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to itsaccuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or theirsecurities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country orother jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject SISL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of SISL.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk.

It should not be considered to be taken as an offer to sell or a solicitation to buy any security. SISL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mailand/or its attachments.

SISL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged inany other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor orlender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

SISL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SISL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or otherdeals in these securities from time to time or may deal in other securities of the companies / organizations described in this report.

SISL, SEBI Reg. No.:INB/F/E 231079832, INB/F/E 011079838, IN-DP-32-2015, AMFI Reg. No. ARN: 78041, SEBI Research Analyst Reg. No.: INH100005011, CIN - U67120UP1994PLC050209